Q1 2022 13F Holders as of 3/31/2022
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
207M
-
Number of holders
-
118
-
Total 13F shares, excl. options
-
51.7M
-
Shares change
-
-1.54M
-
Total reported value, excl. options
-
$240M
-
Value change
-
-$9.96M
-
Put/Call ratio
-
0.29
-
Number of buys
-
66
-
Number of sells
-
-49
-
Price
-
$4.64
Significant Holders of Esperion Therapeutics, Inc. - Common Stock, par value $0.001 per share (ESPR) as of Q1 2022
155 filings reported holding ESPR - Esperion Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q1 2022.
Esperion Therapeutics, Inc. - Common Stock, par value $0.001 per share (ESPR) has 118 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 51.7M shares
of 207M outstanding shares and own 24.92% of the company stock.
Largest 10 shareholders include WASATCH ADVISORS INC (8.15M shares), Deep Track Capital, LP (6M shares), VANGUARD GROUP INC (4.49M shares), Meditor Group Ltd (4.47M shares), Bellevue Group AG (4.3M shares), BlackRock Inc. (3.76M shares), PLATINUM INVESTMENT MANAGEMENT LTD (2.71M shares), Altium Capital Management LP (2.5M shares), MILLENNIUM MANAGEMENT LLC (1.25M shares), and Paradigm Biocapital Advisors LP (1.16M shares).
This table shows the top 118 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.